Onpattro approved in Europe as ICER says not cost-effective

The European Commission approved Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for hereditary transthyretin (TTR)-mediated amyloidosis (hATTR), a day after the Institute for Clinical and Economic Review concluded the drug is not cost-effective based on its U.S. price.

In the EU, Onpattro is indicated to treat hATTR in adults with stage

Read the full 501 word article

User Sign In